@article{oai:shiga-med.repo.nii.ac.jp:00000149,
 author = {河野, 直明 and 邵, 啓全 and 津川, 拓也 and 村田, 喜代史 and 野間, 和夫 and 本多, 恵理子 and 橋本, 惠次 and 近藤, 康雄 and Ushida, Hiroshi and 岡本, 圭生 and 岡田, 裕作},
 issue = {1},
 journal = {滋賀医科大学雑誌},
 month = {Nov},
 note = {Departmental Bulletin Paper, We report the 5-year prostate-specific antigen (PSA) relapse-free survival outcome and incidence of toxicity forpatients with clinically Stage C prostate cancer treated with intensity-modulated radiation therapy (IMRT) in our institute. Atotal of 35 patients with Stage C prostate cancer were treated with IMRT between July 2003 and November 2007. All patientswere treated to a dose of 74Gy prescribed to the planning target volume and received neoadjuvant hormone therapy. Themedian age was 71 years (range: 50 to 80 years). 3 patients (8.6%) had Gleason scores ＜or=6, 14 patients (40.0%) hadGleason scores 7, 18 patients (51.4%) had Gleason scores >or=8. The median pretreatment PSA level was 28.0 ng/mL (range:5.1 to 160.0 ng/mL). Patients were characterized as having high risk disease if their pretreatment PSA level was >20ng/ml andGleason score >or=8. PSA relapse-free survival rate were calculated and toxicity data were scored according to the CommonTerminology Criteria for Adverse Events Version 3.0. The median follow-up time was 58 months (range 7 to 84). 11 patients(31.4%) developed a PSA relapse, and the 5-year PSA relapse-free survival rate was 66.3%. The 5-year PSA relapse-freesurvival rates for high risk patients and others were 39.2% and 85.7%, respectively (p=0.0098). The likelihood of acute grade 2urinary and rectal toxicity was 14.2% and 11.4%. No grade 2 late complications have been observed. These results indicatedthat 74Gy IMRT is well tolerated and is associated with good PSA relapse-free survival outcomes in patients with Stage Cprostate cancer, especially non-high risk patient.},
 pages = {6--12},
 title = {Stage C 前立腺癌に対する内分泌ホルモン療法併用強度変調放射線治療（IMRT）の中期治療成績},
 volume = {26},
 year = {2012}
}